GPX4 and lung carcinoma: SLC7A11 and AIFM2 expression correlated with GPX4 inhibitors’ AUC (i.e., resistance to RSL3, ML162, and ML210) in lung cancer CLs, in agreement with the previously reported correlation in non-hematopoietic CLs in general.32